SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Savara Inc (SVRA) (CIK 0001160308) (SVRA) — Jul 12, 2021

Savara Inc (SVRA) (CIK 0001160308)
Date: July 12, 2021 · CIK: 0001160308 · Accession: 0000000000-21-008598

AI Filing Summary & Sentiment

File numbers found in text: 333-257709

Date
July 12, 2021
Author
Not clearly detected
Form
UPLOAD
Company
Savara Inc (SVRA) (CIK 0001160308)

Letter

United States securities and exchange commission logo July 12, 2021 Matthew Pauls Chief Executive Officer Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 Re:Savara Inc. Registration Statement on Form S-3 Filed July 6, 2021 File No. 333-257709 Dear Mr. Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 or Fredrick Philantrope at (202) 551- 6875 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: J. Robert Suffoletta, Esq.

Show Raw Text
United States securities and exchange commission logo
July 12, 2021
Matthew Pauls
Chief Executive Officer
Savara Inc.
6836 Bee Cave Road
Building III, Suite 200
Austin, TX 78746
Re:Savara Inc.
Registration Statement on Form S-3
Filed July 6, 2021
File No. 333-257709
Dear Mr. Pauls:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 or Fredrick Philantrope at (202) 551-
6875 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       J. Robert Suffoletta, Esq.